195 related articles for article (PubMed ID: 21707510)
1. A novel small molecule inhibitor of FAK and IGF-1R protein interactions decreases growth of human esophageal carcinoma.
Ucar DA; Cox A; He DH; Ostrov DA; Kurenova E; Hochwald SN
Anticancer Agents Med Chem; 2011 Sep; 11(7):629-37. PubMed ID: 21707510
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting the interaction of cMET and IGF-1R with FAK effectively reduces growth of pancreatic cancer cells in vitro and in vivo.
Ucar DA; Magis AT; He DH; Lawrence NJ; Sebti SM; Kurenova E; Zajac-Kaye M; Zhang J; Hochwald SN
Anticancer Agents Med Chem; 2013 May; 13(4):595-602. PubMed ID: 23272972
[TBL] [Abstract][Full Text] [Related]
3. Disruption of the protein interaction between FAK and IGF-1R inhibits melanoma tumor growth.
Ucar DA; Kurenova E; Garrett TJ; Cance WG; Nyberg C; Cox A; Massoll N; Ostrov DA; Lawrence N; Sebti SM; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2012 Sep; 11(17):3250-9. PubMed ID: 22894899
[TBL] [Abstract][Full Text] [Related]
4. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells.
Liu W; Bloom DA; Cance WG; Kurenova EV; Golubovskaya VM; Hochwald SN
Carcinogenesis; 2008 Jun; 29(6):1096-107. PubMed ID: 18263593
[TBL] [Abstract][Full Text] [Related]
5. TAE226, a dual inhibitor for FAK and IGF-IR, has inhibitory effects on mTOR signaling in esophageal cancer cells.
Wang ZG; Fukazawa T; Nishikawa T; Watanabe N; Sakurama K; Motoki T; Takaoka M; Hatakeyama S; Omori O; Ohara T; Tanabe S; Fujiwara Y; Shirakawa Y; Yamatsuji T; Tanaka N; Naomoto Y
Oncol Rep; 2008 Dec; 20(6):1473-7. PubMed ID: 19020730
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profiling of a dual FAK/IGF-1R kinase inhibitor TAE226 in cellular and in vivo tumor models.
Fukami S; Tomioka D; Murakami Y; Honda T; Hatakeyama S
BMC Res Notes; 2019 Jun; 12(1):347. PubMed ID: 31215459
[TBL] [Abstract][Full Text] [Related]
7. Dual tyrosine kinase inhibitor for focal adhesion kinase and insulin-like growth factor-I receptor exhibits anticancer effect in esophageal adenocarcinoma in vitro and in vivo.
Watanabe N; Takaoka M; Sakurama K; Tomono Y; Hatakeyama S; Ohmori O; Motoki T; Shirakawa Y; Yamatsuji T; Haisa M; Matsuoka J; Beer DG; Nagatsuka H; Tanaka N; Naomoto Y
Clin Cancer Res; 2008 Jul; 14(14):4631-9. PubMed ID: 18628478
[TBL] [Abstract][Full Text] [Related]
8. Id1-induced IGF-II and its autocrine/endocrine promotion of esophageal cancer progression and chemoresistance--implications for IGF-II and IGF-IR-targeted therapy.
Li B; Tsao SW; Chan KW; Ludwig DL; Novosyadlyy R; Li YY; He QY; Cheung AL
Clin Cancer Res; 2014 May; 20(10):2651-62. PubMed ID: 24599933
[TBL] [Abstract][Full Text] [Related]
9. Combined Inhibition of IGF-1R/IR and Src family kinases enhances antitumor effects in prostate cancer by decreasing activated survival pathways.
Dayyani F; Parikh NU; Varkaris AS; Song JH; Moorthy S; Chatterji T; Maity SN; Wolfe AR; Carboni JM; Gottardis MM; Logothetis CJ; Gallick GE
PLoS One; 2012; 7(12):e51189. PubMed ID: 23300537
[TBL] [Abstract][Full Text] [Related]
10. A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells.
Zhang J; He DH; Zajac-Kaye M; Hochwald SN
Cell Cycle; 2014; 13(19):3143-9. PubMed ID: 25486573
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of both focal adhesion kinase and insulin-like growth factor-I receptor kinase suppresses glioma proliferation in vitro and in vivo.
Liu TJ; LaFortune T; Honda T; Ohmori O; Hatakeyama S; Meyer T; Jackson D; de Groot J; Yung WK
Mol Cancer Ther; 2007 Apr; 6(4):1357-67. PubMed ID: 17431114
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
[TBL] [Abstract][Full Text] [Related]
13. A novel small molecule inhibitor of FAK decreases growth of human pancreatic cancer.
Hochwald SN; Nyberg C; Zheng M; Zheng D; Wood C; Massoll NA; Magis A; Ostrov D; Cance WG; Golubovskaya VM
Cell Cycle; 2009 Aug; 8(15):2435-43. PubMed ID: 19571674
[TBL] [Abstract][Full Text] [Related]
14. Dual sphingosine kinase inhibitor SKI-II enhances sensitivity to 5-fluorouracil in hepatocellular carcinoma cells via suppression of osteopontin and FAK/IGF-1R signalling.
Grbčić P; Tomljanović I; Klobučar M; Kraljević Pavelić S; Lučin K; Sedić M
Biochem Biophys Res Commun; 2017 Jun; 487(4):782-788. PubMed ID: 28433634
[TBL] [Abstract][Full Text] [Related]
15. Ridaforolimus (MK-8669) synergizes with Dalotuzumab (MK-0646) in hormone-sensitive breast cancer.
Becker MA; Hou X; Tienchaianada P; Haines BB; Harrington SC; Weroha SJ; Sathyanarayanan S; Haluska P
BMC Cancer; 2016 Oct; 16(1):814. PubMed ID: 27765027
[TBL] [Abstract][Full Text] [Related]
16. The association of TP53 mutations with the resistance of colorectal carcinoma to the insulin-like growth factor-1 receptor inhibitor picropodophyllin.
Wang Q; Wei F; Lv G; Li C; Liu T; Hadjipanayis CG; Zhang G; Hao C; Bellail AC
BMC Cancer; 2013 Nov; 13():521. PubMed ID: 24182354
[TBL] [Abstract][Full Text] [Related]
17. Bit1 knockdown contributes to growth suppression as well as the decreases of migration and invasion abilities in esophageal squamous cell carcinoma via suppressing FAK-paxillin pathway.
Fan T; Chen J; Zhang L; Gao P; Hui Y; Xu P; Zhang X; Liu H
Mol Cancer; 2016 Mar; 15():23. PubMed ID: 26956728
[TBL] [Abstract][Full Text] [Related]
18. ERK phosphorylation is predictive of resistance to IGF-1R inhibition in small cell lung cancer.
Zinn RL; Gardner EE; Marchionni L; Murphy SC; Dobromilskaya I; Hann CL; Rudin CM
Mol Cancer Ther; 2013 Jun; 12(6):1131-9. PubMed ID: 23515613
[TBL] [Abstract][Full Text] [Related]
19. Insulin-like growth factor-1 receptor as a novel prognostic marker and its implication as a cotarget in the treatment of human adenocarcinoma of the esophagus.
Kalinina T; Bockhorn M; Kaifi JT; Thieltges S; Güngör C; Effenberger KE; Strelow A; Reichelt U; Sauter G; Pantel K; Izbicki JR; Yekebas EF
Int J Cancer; 2010 Oct; 127(8):1931-40. PubMed ID: 20104520
[TBL] [Abstract][Full Text] [Related]
20. Nordihydroguaiaretic acid inhibits insulin-like growth factor signaling, growth, and survival in human neuroblastoma cells.
Meyer GE; Chesler L; Liu D; Gable K; Maddux BA; Goldenberg DD; Youngren JF; Goldfine ID; Weiss WA; Matthay KK; Rosenthal SM
J Cell Biochem; 2007 Dec; 102(6):1529-41. PubMed ID: 17486636
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
